ArticleJuntendo Iji zasshi = Juntendo medical journal2024
Conceptualizing Treatment Strategies for Diabetic Kidney Disease: the Importance of Early Diagnosis and Treatment.
Article in Juntendo Iji zasshi = Juntendo medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Refining the Cardiovascular-Kidney-Metabolic Staging System for Improved Risk Stratification of Chronic Kidney Disease Progression in Type 2 Diabetes.Circulation reports · 2026Article
- Independent predictive role of nutritional markers in kidney function decline and mortality in diabetes.Metabolism open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) attributed to diabetes, termed diabetic kidney disease (DKD), is increasing with the rising global prevalence of diabetes. Patterns of DKD onset and progression have shifted in recent years because of population aging and advances in the treatment of diabetes. Prevention of the onset and progression of micro/macro-albuminuria is possible through comprehensive and strict management of lifestyle, blood glucose, blood pressure, and lipids in people with diabetes and early DKD. Renin-angiotensin system (RAS) inhibitors have also been shown to effectively slow the progression of CKD in people with diabetes and micro/macro-albuminuria. However, the effect of improving kidney outcomes with RAS inhibitors in people with advanced DKD is limited, and the residual risk remains very high. A recent rapid expansion of treatment options include sodium-glucose co-transporter-2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, and glucagon-like peptide-1 receptor agonists, which have demonstrated additional protective effects for the kidneys when used in addition to the standard therapy with RAS inhibitors, even in people with advanced DKD. Early diagnosis and therapeutic intervention can be expected to delay progression to end-stage kidney failure. This perspective outlines the diagnostic and therapeutic evolution of DKD to date.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.